No Cover Image

Journal article 669 views 64 downloads

Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021

Debasish Banerjee Orcid Logo, Peter Winocour, Tahseen A. Chowdhury, Parijat De, Mona Wahba, Rosa Montero, Damian Fogarty, Andrew Frankel, Gabrielle Goldet, Janaka Karalliedde, Patrick B. Mark, Dipesh Patel, Ana Pokrajac, Adnan Sharif, Sagen Zac-Varghese, Steve Bain Orcid Logo, Indranil Dasgupta Orcid Logo

Kidney International Reports, Volume: 7, Issue: 4, Pages: 681 - 687

Swansea University Author: Steve Bain Orcid Logo

  • 59219.VOR.pdf

    PDF | Version of Record

    © 2022 International Society of Nephrology. Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) Licence.

    Download (658.68KB)

Check full text

DOI (Published version): 10.1016/j.ekir.2022.01.004

Abstract

Diabetic kidney disease accounts for over 40% cases of chronic kidney disease globally. Hypertension is a major risk factor for progression of diabetic kidney disease and the high incidence of cardiovascular disease and mortality in these people. Meticulous management of hypertension is therefore cr...

Full description

Published in: Kidney International Reports
ISSN: 2468-0249
Published: Elsevier BV 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa59219
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-01-20T11:54:45Z
last_indexed 2023-01-11T14:40:20Z
id cronfa59219
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-12-02T18:42:07.9083295</datestamp><bib-version>v2</bib-version><id>59219</id><entry>2022-01-20</entry><title>Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-01-20</date><deptcode>BMS</deptcode><abstract>Diabetic kidney disease accounts for over 40% cases of chronic kidney disease globally. Hypertension is a major risk factor for progression of diabetic kidney disease and the high incidence of cardiovascular disease and mortality in these people. Meticulous management of hypertension is therefore crucial to slow down the progression of diabetic kidney disease and reduce cardiovascular risk. Randomized controlled trial evidence differs in type 1 and type 2 diabetes and in different stages of diabetic kidney disease in terms of target blood pressure. Renin angiotensin blocking agents reduce progression of diabetic kidney disease and cardiovascular events in both type 1 and type 2 diabetes, albeit differently according to the stage of chronic kidney disease. There is emerging evidence for the benefit of sodium glucose co-transporter-2, non-steroidal selective mineralocorticoid antagonists and endothelin-A receptor antagonists in slowing progression and reducing cardiovascular events in diabetic kidney disease. This UK guideline, developed jointly by diabetologists and nephrologists, has reviewed all available current evidence regarding the management of hypertension in DKD to produce a set of comprehensive individualized recommendations for blood pressure control and the use of antihypertensive agents according to age, type of diabetes and stage of chronic kidney disease (https://ukkidney.org/sites/renal.org/files/Management-of-hypertension-and-RAAS-blockade-in-adults-with-DKD.pdf). A succinct summary of the guideline including an infographic is presented here.</abstract><type>Journal Article</type><journal>Kidney International Reports</journal><volume>7</volume><journalNumber>4</journalNumber><paginationStart>681</paginationStart><paginationEnd>687</paginationEnd><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2468-0249</issnPrint><issnElectronic/><keywords>diabetes; hypertension; chronic kidney disease; dialysis; ACE inhibitors; angiotensin receptor blockers</keywords><publishedDay>1</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-04-01</publishedDate><doi>10.1016/j.ekir.2022.01.004</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-12-02T18:42:07.9083295</lastEdited><Created>2022-01-20T11:46:23.5723956</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Debasish</firstname><surname>Banerjee</surname><orcid>0000-0002-6863-2325</orcid><order>1</order></author><author><firstname>Peter</firstname><surname>Winocour</surname><order>2</order></author><author><firstname>Tahseen A.</firstname><surname>Chowdhury</surname><order>3</order></author><author><firstname>Parijat</firstname><surname>De</surname><order>4</order></author><author><firstname>Mona</firstname><surname>Wahba</surname><order>5</order></author><author><firstname>Rosa</firstname><surname>Montero</surname><order>6</order></author><author><firstname>Damian</firstname><surname>Fogarty</surname><order>7</order></author><author><firstname>Andrew</firstname><surname>Frankel</surname><order>8</order></author><author><firstname>Gabrielle</firstname><surname>Goldet</surname><order>9</order></author><author><firstname>Janaka</firstname><surname>Karalliedde</surname><order>10</order></author><author><firstname>Patrick B.</firstname><surname>Mark</surname><order>11</order></author><author><firstname>Dipesh</firstname><surname>Patel</surname><order>12</order></author><author><firstname>Ana</firstname><surname>Pokrajac</surname><order>13</order></author><author><firstname>Adnan</firstname><surname>Sharif</surname><order>14</order></author><author><firstname>Sagen</firstname><surname>Zac-Varghese</surname><order>15</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>16</order></author><author><firstname>Indranil</firstname><surname>Dasgupta</surname><orcid>0000-0002-7448-2677</orcid><order>17</order></author></authors><documents><document><filename>59219__23957__e4c809defcf54d219fecebf8238dc8bb.pdf</filename><originalFilename>59219.VOR.pdf</originalFilename><uploaded>2022-05-03T11:48:48.7022320</uploaded><type>Output</type><contentLength>674488</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2022 International Society of Nephrology. Creative Commons Attribution &#x2013; NonCommercial &#x2013; NoDerivs (CC BY-NC-ND 4.0) Licence.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-12-02T18:42:07.9083295 v2 59219 2022-01-20 Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2022-01-20 BMS Diabetic kidney disease accounts for over 40% cases of chronic kidney disease globally. Hypertension is a major risk factor for progression of diabetic kidney disease and the high incidence of cardiovascular disease and mortality in these people. Meticulous management of hypertension is therefore crucial to slow down the progression of diabetic kidney disease and reduce cardiovascular risk. Randomized controlled trial evidence differs in type 1 and type 2 diabetes and in different stages of diabetic kidney disease in terms of target blood pressure. Renin angiotensin blocking agents reduce progression of diabetic kidney disease and cardiovascular events in both type 1 and type 2 diabetes, albeit differently according to the stage of chronic kidney disease. There is emerging evidence for the benefit of sodium glucose co-transporter-2, non-steroidal selective mineralocorticoid antagonists and endothelin-A receptor antagonists in slowing progression and reducing cardiovascular events in diabetic kidney disease. This UK guideline, developed jointly by diabetologists and nephrologists, has reviewed all available current evidence regarding the management of hypertension in DKD to produce a set of comprehensive individualized recommendations for blood pressure control and the use of antihypertensive agents according to age, type of diabetes and stage of chronic kidney disease (https://ukkidney.org/sites/renal.org/files/Management-of-hypertension-and-RAAS-blockade-in-adults-with-DKD.pdf). A succinct summary of the guideline including an infographic is presented here. Journal Article Kidney International Reports 7 4 681 687 Elsevier BV 2468-0249 diabetes; hypertension; chronic kidney disease; dialysis; ACE inhibitors; angiotensin receptor blockers 1 4 2022 2022-04-01 10.1016/j.ekir.2022.01.004 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-12-02T18:42:07.9083295 2022-01-20T11:46:23.5723956 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Debasish Banerjee 0000-0002-6863-2325 1 Peter Winocour 2 Tahseen A. Chowdhury 3 Parijat De 4 Mona Wahba 5 Rosa Montero 6 Damian Fogarty 7 Andrew Frankel 8 Gabrielle Goldet 9 Janaka Karalliedde 10 Patrick B. Mark 11 Dipesh Patel 12 Ana Pokrajac 13 Adnan Sharif 14 Sagen Zac-Varghese 15 Steve Bain 0000-0001-8519-4964 16 Indranil Dasgupta 0000-0002-7448-2677 17 59219__23957__e4c809defcf54d219fecebf8238dc8bb.pdf 59219.VOR.pdf 2022-05-03T11:48:48.7022320 Output 674488 application/pdf Version of Record true © 2022 International Society of Nephrology. Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) Licence. true eng http://creativecommons.org/licenses/by-nc-nd/4.0/
title Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021
spellingShingle Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021
Steve Bain
title_short Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021
title_full Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021
title_fullStr Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021
title_full_unstemmed Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021
title_sort Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Debasish Banerjee
Peter Winocour
Tahseen A. Chowdhury
Parijat De
Mona Wahba
Rosa Montero
Damian Fogarty
Andrew Frankel
Gabrielle Goldet
Janaka Karalliedde
Patrick B. Mark
Dipesh Patel
Ana Pokrajac
Adnan Sharif
Sagen Zac-Varghese
Steve Bain
Indranil Dasgupta
format Journal article
container_title Kidney International Reports
container_volume 7
container_issue 4
container_start_page 681
publishDate 2022
institution Swansea University
issn 2468-0249
doi_str_mv 10.1016/j.ekir.2022.01.004
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Diabetic kidney disease accounts for over 40% cases of chronic kidney disease globally. Hypertension is a major risk factor for progression of diabetic kidney disease and the high incidence of cardiovascular disease and mortality in these people. Meticulous management of hypertension is therefore crucial to slow down the progression of diabetic kidney disease and reduce cardiovascular risk. Randomized controlled trial evidence differs in type 1 and type 2 diabetes and in different stages of diabetic kidney disease in terms of target blood pressure. Renin angiotensin blocking agents reduce progression of diabetic kidney disease and cardiovascular events in both type 1 and type 2 diabetes, albeit differently according to the stage of chronic kidney disease. There is emerging evidence for the benefit of sodium glucose co-transporter-2, non-steroidal selective mineralocorticoid antagonists and endothelin-A receptor antagonists in slowing progression and reducing cardiovascular events in diabetic kidney disease. This UK guideline, developed jointly by diabetologists and nephrologists, has reviewed all available current evidence regarding the management of hypertension in DKD to produce a set of comprehensive individualized recommendations for blood pressure control and the use of antihypertensive agents according to age, type of diabetes and stage of chronic kidney disease (https://ukkidney.org/sites/renal.org/files/Management-of-hypertension-and-RAAS-blockade-in-adults-with-DKD.pdf). A succinct summary of the guideline including an infographic is presented here.
published_date 2022-04-01T04:16:21Z
_version_ 1763754095993159680
score 11.012947

Similar Items